Socioeconomic and insurance‐related disparities in disease‐specific survival among patients with metastatic bone disease

Background Approximately 5% of cancer patients in the United States presented with metastatic bone disease (MBD) at diagnosis. Current study explores the disparities in survival for patients with MBD. Methods Patients with the diagnosis of MBD at presentation for the five most common primary anatomi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2023-01, Vol.127 (1), p.159-173
Main Authors: Jawad, Muhammad Umar, Pollock, Brad H., Wise, Barton L., Zeitlinger, Lauren N., O' Donnell, Edmond F., Carr‐Ascher, Janai R., Cizik, Amy, Ferrell, Betty, Thorpe, Steven W., Randall, R. Lor
Format: Article
Language:English
Subjects:
Bone diseases
disparities
insurance
Medical prognosis
Metastasis
metastatic bone disease
Prostate
socioeconomic
Socioeconomic factors
survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Approximately 5% of cancer patients in the United States presented with metastatic bone disease (MBD) at diagnosis. Current study explores the disparities in survival for patients with MBD. Methods Patients with the diagnosis of MBD at presentation for the five most common primary anatomical sites were extracted from Surveillance, Epidemiology, and End Results Census tract–level dataset (2010–2016). Kaplan–Meier and Cox Proportional Hazard models were used to evaluate survival, and prognostic factors for each cohort. Prognostic significance of socioeconomic status (SES) and insurance status were ascertained. Results The five most common anatomical‐sites with MBD at presentation included “lung” (n = 59 739), “prostate” (n = 19 732), “breast” (n = 16 244), “renal and urothelium” (n = 7718) and “colon” (n= 3068). Lower SES was an independent risk factor for worse disease‐specific survival (DSS) for patients with MBD originating from lung, prostate, breast and colon. Lack of insurance was an independent risk factor for worse DSS for MBD patients with primary tumors in lung and breast. Conclusions MBD patients from the five most common primary sites demonstrated SES and insurance‐related disparities in disease‐specific survival. This is the first and largest study to explore SES and insurance‐related disparities among patients specifically afflicted with MBD. Our findings highlight vulnerability of patients with MBD across multiple primary sites to financial toxicity.
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.27097